Academic Outcomes TAVR 
DAIC
MARCH 12, 2024
milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.
Open Heart
JANUARY 19, 2023
Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
Dr. S. Venkatesan MD
FEBRUARY 9, 2024
Reviewing NOTION study, the Nordic TAVI 10 year follow up has just been released (Ref 1) : Caution : Non-academic content This study reports the long-term outcome in low-risk individuals who required AVR. Now, some academic queries ? Was the outcome assessment blinded ? Was CAD accounted for outcome difference ?
Cardiology Update
APRIL 9, 2024
The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure. The percent change from baseline in fasting TG at six months served as the primary outcome measure. A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve.
DAIC
MARCH 21, 2024
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for cardiologists, hands-down. The best possible outcome of this situation is inefficient workflow, driving higher overall cost of care and resulting in widespread physician and patient frustration. Why is that?
Expert insights. Personalized for you.
52 
Let's personalize your content